$Regencell Bioscience(RGC.US) has dropped another -14%. It was previously pushed up by a short squeeze, but now it's under pressure from a DOJ investigation, class-action lawsuits, and widening losses. For this kind of purely sentiment-driven small-cap Chinese medicine concept stock that's falling, does it count as an opportunity? I won't touch it myself — the decline of a squeeze stock usually isn't a one-off event. Once the shareholding structure loosens, any rebound won't be able to retain investors.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
